TABLE 6.
Baseline characteristics of different vaccine combinations.
| Variable | 3x BNT162b2 | 2x BNT162b2, 1x 1273 | 2x 1273, 1x BNT162b2 | 3x 1273 | 2x mRNA, 1x vector | 2x mRNA | |
| Number | Evaluable | 57 | 22 | 16 | 63 | 8 | 67 |
| Age (years) | Mean ± SD | 55.6 ± 15.5 | 60 ± 13.4 | 58.9 ± 13.3 | 59.9 ± 12.3 | 60.8 ± 7.4 | 57.1 ± 12.9 |
| Male Sex | n/% | 39/68.4 | 19/86.4 | 9/56.2 | 45/71.4 | 5/62.5 | 40/59.7 |
| BMI (kg/m2) | Mean ± SD | 25.6 ± 4.9 | 26.1 ± 3.7 | 26.3 ± 4.3 | 25.8 ± 4.6 | 28.8 ± 9.9 | 26.2 ± 5 |
| Cause of end stage renal disease | n/% | 36/63.2 | 16/72.7 | 12/75 | 29/46 | 6/75 | 44/65.7 |
| Diabetes-hypertension-vascular disease | n/% | 13/22.8 | 2/9.1 | 4/25 | 11/17.5 | 2/25 | 10/14.9 |
| Glomerulonephritis-interstitial nephritis | n/% | 13/22.8 | 9/40.9 | 7/43.8 | 9/14.3 | 3/37.5 | 21/31.3 |
| Vasculitis | n/% | 3/5.3 | 1/4.5 | 1/6.2 | 0/0 | 1/12.5 | 2/3 |
| Polycystic kidney disease | n/% | 7/12.3 | 4/18.2 | 0/0 | 9/14.3 | 0/0 | 11/16.4 |
| Unknown | n/% | 21/36.8 | 6/27.3 | 4/25 | 34/54 | 2/25 | 23/34.3 |
| Drug treated comorbidities | n/% | 51/89.5 | 21/95.5 | 14/87.5 | 56/88.9 | 7/87.5 | 60/89.6 |
| Diabetes mellitus | n/% | 14/24.6 | 3/13.6 | 2/12.5 | 10/15.9 | 3/37.5 | 7/10.4 |
| Cardiovascular disease | n/% | 46/80.7 | 21/95.5 | 14/87.5 | 56/88.9 | 6/75 | 60/89.6 |
| Lung disease | n/% | 5/8.8 | 0/0 | 1/6.2 | 4/6.3 | 1/12.5 | 6/9 |
| Liver cirrhosis | n/% | 2/3.5 | 1/4.5 | 0/0 | 0/0 | 0/0 | 0/0 |
| Cancer | n/% | 2/3.5 | 1/4.5 | 0/0 | 0/0 | 0/0 | 2/3 |
| None | n/% | 6/10.5 | 1/4.5 | 2/12.5 | 7/11.1 | 1/12.5 | 7/10.4 |
| Time on dialysis (years) | Mean ± SD | 6.3 ± 6.9 | 5.8 ± 3.5 | 8.9 ± 9.2 | 5.3 ± 4.5 | 7.7 ± 4.2 | 6 ± 6.8 |
| Time on transplantation (years) | Mean ± SD | 6.9 ± 6 | 8.4 ± 5.7 | 8.8 ± 7.6 | 9.3 ± 5.8 | 6.4 ± 7.3 | 10 ± 6.9 |
| Previous transplantation | n/% | 9/15.8 | 5/22.7 | 3/18.8 | 5/7.9 | 1/12.5 | 8/11.9 |
| Hepatitis B vaccination failure | n/% | 4/7 | 1/4.5 | 0/0 | 3/4.8 | 1/12.5 | 5/7.5 |
| Flu vaccination winter 2020/2021 | n/% | 26/45.6 | 16/72.7 | 10/62.5 | 33/52.4 | 5/62.5 | 46/68.7 |
| On immunosuppressive therapy | n/% | 57/100 | 22/100 | 16/100 | 63/100 | 8/100 | 67/100 |
| Corticosteroids | n/% | 28/49.1 | 10/45.5 | 13/81.2 | 24/38.1 | 3/37.5 | 35/52.2 |
| Calcineurin-inhibitor | n/% | 51/89.5 | 19/86.4 | 16/100 | 60/95.2 | 8/100 | 63/94 |
| MMF/MPA | n/% | 49/86 | 19/86.4 | 14/87.5 | 57/90.5 | 7/87.5 | 62/92.5 |
| mTOR-inhibitor | n/% | 9/15.8 | 5/22.7 | 1/6.2 | 3/4.8 | 0/0 | 5/7.5 |
| Belatacept | n/% | 6/10.5 | 1/4.5 | 0/0 | 5/7.9 | 0/0 | 4/6 |
| T-cell depleting ab | n/% | 0/0 | 0/0 | 0/0 | 0/0 | 0/0 | 0/0 |
| B-cell depleting ab n | n/% | 0/0 | 0/0 | 0/0 | 1/1.6 | 0/0 | 0/0 |
| Other | n/% | 0/0 | 0/0 | 1/6.2 | 1/1.6 | 0/0 | 1/1.5 |
BNT162b2 = BNT162b2-mRNA or tozinameran or brand name Comirnaty; 1273 = 1273-mRNA or brand name Spikevax; vector = vector vaccine consisting of AZD1222 in 5 cases and Ad26.COV2.S in 3 cases.
For this evaluation, all patients with asymptomatic* or documented symptomatic** COVID-19 disease before and during vaccination up to T3 (6 months) were excluded.
Hepatitis B vaccination failure definition–patients with unsuccessful vaccination after at least four attempts; MMF-MPA = mycophenolate mofetil or mycophenolic acid.
*Asymptomatic COVID-19 disease definition–neither knowledge nor symptoms of COVID-19 disease, but IgG-antibody reaction to nucleocapsid (T0, T1, T2, or T3) or the Spike protein subunit S1 (only T0) of the SARS-CoV-2 virus is positive.
**Symptomatic COVID-19 disease definition–SARS-CoV-2 PCR positive patients with clinical symptoms.